Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Petersen, E. et al. Lancet Infect. Dis. https://doi.org/10.1016/S1473-3099(20)30484-9 (2020).
Li, C. et al. Immunity 46, 446–456 (2017).
Liu, S. Y. et al. Immunity 38, 92–105 (2013).
Lund, E. G. et al. J. Biol. Chem. 273, 34316–34327 (1998).
Adams, C. M. et al. J. Biol. Chem. 279, 52772–52780 (2004).
Shen, B. et al. Cell 182, 59–72 e15 (2020).
Wu, D. et al. Natl Sci. Rev. 7, 1157–1168 (2020).
Sun, S. H. et al. Cell Host Microbe 28, 124–133 e4 (2020).
Nie, J. et al. Emerg. Microbes Infect. 9, 680–686 (2020).
Gu, H. et al. Science https://doi.org/10.1126/science.abc4730 (2020).
Anggakusuma et al. Hepatology 62, 702–714 (2015).
Wang, M. et al. Cell Res. 30, 269–271 (2020).
Liu, J. et al. Cell Discov. 6, 16 (2020).
Acknowledgements
We thank Drs. Youchun Wang and Weijin Huang for providing the SARS-CoV-2 pseudovirus system. We thank Dr. Saba Roghiyh Aliyari, Yanan Wang, Na-Na Zhang, Rong-Rong Zhang, Tian-Shu Cao and Yan Guo for critical reagents and helpful discussion. This project is supported by the Chinese Academy of Medical Sciences Initiative for Innovative Medicine (2019-I2M-5-049, 2016-I2M-1-005), Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences (2019XK310002), the National Natural Science Foundation of China (91542201, 81925025 and 81802870), NIH R01AI069120, AI158154 and AI140718 grants, University of California Los Angeles (UCLA) AI and Charity Treks, UCLA DGSOM BSCRC COVID-19 Award Program, and the National Key Research and Development Project (2020YFC0841700).
Author information
Authors and Affiliations
Contributions
C.-F.Q., G.C. and H.Y. conceived and designed the experiments. S.Z., Y.-Q.D. and C.Z. performed the majority of the experiments and analyzed the data. J.L. collected serum from healthy individuals and the patient. J.H. performed the drug granules toxicity test. X.L. and C.Z produced the drug granules. X.-F.L., Q.C., H.Z. and L.L. helped specific experiments and data analysis. S.Z. wrote the original draft of the manuscript. Y.-Q.D., S.G. and C.Z. helped revise the manuscript. All authors read and approved the contents of the manuscript.
Corresponding authors
Ethics declarations
Competing interests
C.-F.Q. and H.Y. have filed a patent related to the antiviral activity of 25HC. X.L. is employee of Porton Biologics Ltd. C.Z. is employee of CoSci Me-Tech Co., Ltd.
Supplementary information
Rights and permissions
About this article
Cite this article
Zu, S., Deng, YQ., Zhou, C. et al. 25-Hydroxycholesterol is a potent SARS-CoV-2 inhibitor. Cell Res 30, 1043–1045 (2020). https://doi.org/10.1038/s41422-020-00398-1
Received:
Accepted:
Published:
Version of record:
Issue date:
DOI: https://doi.org/10.1038/s41422-020-00398-1
This article is cited by
-
Hidden in plain sight: the impact of human rhinovirus infection in adults
Respiratory Research (2025)
-
Interferon-stimulated gene PVRL4 broadly suppresses viral entry by inhibiting viral-cellular membrane fusion
Cell & Bioscience (2024)
-
In silico molecular screening of bioactive natural compounds of rosemary essential oil and extracts for pharmacological potentials against rhinoviruses
Scientific Reports (2024)
-
Cholesterol inhibition enhances antitumor response of gilteritinib in lung cancer cells
Cell Death & Disease (2024)
-
Recent progress on drugs discovery study for treatment of COVID-19: repurposing existing drugs and current natural bioactive molecules
Applied Biological Chemistry (2023)
